Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study

Launched by UNIVERSITY OF WASHINGTON · Jul 10, 2020

Keywords

ClinConnect Summary

The PATROL Study is a clinical trial focused on finding better ways to detect prostate cancer earlier in men who have a higher genetic risk for aggressive forms of the disease. Researchers aim to analyze samples of blood, urine, and tissue to better understand the genetics behind prostate cancer. This could lead to improved methods for early detection and treatment, ultimately helping to save lives.

To participate in this study, men must be at least 40 years old and have a known genetic mutation linked to increased prostate cancer risk. However, men who have already been diagnosed with prostate cancer or have undergone cancer treatment in the past year are not eligible. Participants can expect to provide samples and complete specific medical tests as part of the study, all while being closely monitored by the research team. This trial is currently recruiting participants, and involvement could contribute to important advancements in prostate cancer care.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • People with prostates ≥40 years of age
• • Documented germline pathogenic variant in known or suspected genes associated with prostate cancer risk.
• Exclusion Criteria:
• • Prior diagnosis of prostate cancer
• • Medical contraindication to any of the study procedures (e.g., prostate biopsy)
• • For all cancer types except non-melanoma skin cancer, any cancer treatment with curative intent within the past 12 months (e.g., surgery, radiation, chemotherapy, immunotherapy)
• • Prior or concurrent participation in an interventional clinical trial aimed at preventing cancer for people with germline variants associated with increased prostate cancer risk
• • Unable to provide written informed consent
• • Unable or unwilling to complete clinical care and study procedures as indicated by the study protocol.